ReviewCurrent cardiology reports2018
Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.
Review in Current cardiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review.Heart failure reviews · 2020Pooled it
- Cost Effectiveness Analysis Rivaroxaban Plus Aspirin versus Aspirin alone in Treatment Cardiovascular Diseases: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2024Review
- Alirocumab in Post ACS Patients - Saving Lives at a Premium.Current cardiology reviews · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to explore and summarize the current literature on the cardiovascular disease (CVD) healthcare burden and determine the cost-effectiveness of the PCSK9 inhibitors. RECENT
findingsThe CVD remain the largest cause of mortality in the USA presenting substantial healthcare cost burden reaching $555 billion in 2016 and projected to rise to $1.1 trillion by 2035. The PCSK9 inhibitors have shown strong efficacy in LDLC lowering, but its price of ~ 14,000-14,600 per patient per year coupled with ~ 2.2-2.8 years of cardiovascular outcome data has created many controversies surrounding its cost-effectiveness. To determine the cost-effectiveness of the PCSK9 inhibitors, various simulation models and risk-based stratification and case-by-case patient approachs have yielded divisive data which need to be reassessed as per the ODYSSEY and long-term CVD outcomes. Further studies are warranted to evaluate the long-term CVD event rates of patients on the PCSK9 inhibitors to determine its true cost-effectiveness.
Indexed as
Identifiers
29779055What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.